Incentivizing Breakthroughs

With scientific funding on shaky ground, big-dollar competitions offer a new way for life-science innovators to bring their ideas to fruition.

Written byGrant Campany
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

© ISTOCKPHOTO.COM/VLADGRINMuch consternation has been voiced about decreases in government funding for scientific research and discovery and what these funding slumps portend for the future of science, as well as for our economy and job market. In March, National Institutes of Health Director Francis Collins told The New York Times that 2013 was “one of his agency’s darkest years ever, with fewer grants awarded and with jobs and programs cut.” In the meantime, funding has also dwindled on another front, as venture capital investors are increasingly placing their bets on more-mature companies with products in later stages of development. According to the most recent EY Medical Technology Report 2013, venture capital investment was down 21 percent from 2012 to 2013, dropping to its lowest level in more than a decade.

Some inventors and innovators find themselves in a difficult spot, having advanced products beyond basic research—so that they do not usually qualify for government funding—but not near enough to commercialization to appeal to venture capitalists. To avoid this mid-stage “Valley of Death,” life-science and technology innovators are spending more of their time searching for new funding sources. The Internet, with its reach and speed powered by social networking, provides a platform for crowdfunding, an area that is expected to grow over the next 10 years. Contributions from angel investors—typically well-connected, wealthy individuals who invest their own money— and incubator sources have doubled since 2007 in the U.S. and increased more than fivefold in Europe. However, these sources have high aversion to risk. There is another ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies